Últimos Artículos de Endocrine Related Cancer
- ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
- Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study
- AGEs induce MMP-9 promoter demethylation through the GADD45α-mediated BER pathway to promote breast cancer metastasis in patients with diabetes
- Genetic variants and down-regulation of CACNA1H in pheochromocytoma
- Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland
- Disease relapse in relation to lymph node sampling in lung carcinoid patients
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy
- The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis
- Changes in categorization or nomenclature within neuroendocrine tumors
- Advancements and challenges in pheochromocytoma and paraganglioma research: a collection of insights
- EPAS1-related pheochromocytoma/paraganglioma
- Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
- Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer
- A zebrafish xenotransplant model of anaplastic thyroid cancer to study tumor microenvironment and innate immune cell interactions in vivo
- Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis
- Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms
- Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis
- HSPB1 promotes tumor invasion by inducing angiogenesis in PitNETs
- Genetic disorders and insulinoma/glucagonoma
- Glucagon and insulin: 100 years young